Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Myeloid Leukemia, Chronic Phase: early-phase trial registry
2 of 4 indexed Chronic Myeloid Leukemia, Chronic Phase trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Chronic Myeloid Leukemia, Chronic Phase: 4 US clinical trials tracked, 2 recruiting.
Chronic Myeloid Leukemia, Chronic Phase is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Terns, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-myeloid-leukemia-chronic-phase
OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Chronic Myeloid Leukemia, Chronic Phase lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Myeloid Leukemia, Chronic Phase on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Myeloid Leukemia, Chronic Phase is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns
NCT06163430
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Augusta University
NCT05143840
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
NCT03610971
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
NCT03885830
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Myeloid Leukemia, Chronic Phase records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Myeloid Leukemia, Chronic Phase trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Myeloid Leukemia, Chronic Phase page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Chronic Myeloid Leukemia, Chronic Phase trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Terns sponsors the most Chronic Myeloid Leukemia, Chronic Phase trials on record, review their full trial history before evaluating a specific study. See Terns's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Myeloid Leukemia, Chronic Phase condition card totals 4 registered trials; most-linked intervention BCR-ABL Tyrosine Kinase Inhibitor (TKI); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.